Strategies to reduce hepatitis C virus recurrence after liver transplantation

World Journal of Hepatology

Volumn 5, Issue 5, 2013, Pages 237-250

  Ciria, Ruben ^a   Pleguezuelo, María ^b   Khorsandi, Shirin Elizabeth ^a   Davila, Diego ^a   Suddle, Abid ^a   Vilca Melendez, Hector ^a   Rufian, Sebastian ^b   de la Mata, Manuel ^b   Briceño, Javier ^b   Cillero, Pedro López ^b   Heaton, Nigel ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

Hepatitis C virus; Liver; Outcomes; Recurrence; Transplantation

Indexed keywords

EID: 84879135611     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v5.i5.237     Document Type: Article

References (120)

1. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345: 41-52 [PMID: 11439948 DOI: 10.1056/ NEJM200107053450107]
2. Neumann UP, Berg T, Bahra M, Puhl G, Guckelberger O, Langrehr JM, Neuhaus P. Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up. Transplantation 2004; 77: 226-231 [PMID: 14742986 DOI: 10.1002/ lt.21644]
3. Ramírez S, Pérez-Del-Pulgar S, Forns X. Virology and pathogenesis of hepatitis C virus recurrence. Liver Transpl 2008; 14 Suppl 2: S27-S35 [PMID: 18825723]
4. Llado L, Castellote J, Figueras J. Is retransplantation an option for recurrent hepatitis C cirrhosis after liver transplantation? J Hepatol 2005; 42: 468-472 [PMID: 15763328 DOI: 10.1016/j.jhep.2005.01.014]
5. Pelletier SJ, Iezzoni JC, Crabtree TD, Hahn YS, Sawyer RG, Pruett TL. Prediction of liver allograft fibrosis after transplantation for hepatitis C virus: persistent elevation of serum transaminase levels versus necroinflammatory activity. Liver Transpl 2000; 6: 44-53 [PMID: 10648577 DOI: 10.1016/ S1527-6465(00)80032-5]
6. Gane EJ, Portmann BC, Naoumov NV, Smith HM, Underhill JA, Donaldson PT, Maertens G, Williams R. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996; 334: 815-820 [PMID: 8596547 DOI: 10.1056/ NEJM199603283341302]
7. Carrión JA, Navasa M, Bosch J, Bruguera M, Gilabert R, Forns X. Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis C recurrence after liver transplantation. Liver Transpl 2006; 12: 1791-1798 [PMID: 16823833 DOI: 10.1002/lt.20857]
8. Ballardini G, De Raffele E, Groff P, Bioulac-Sage P, Grassi A, Ghetti S, Susca M, Strazzabosco M, Bellusci R, Iemmolo RM, Grazi G, Zauli D, Cavallari A, Bianchi FB. Timing of reinfection and mechanisms of hepatocellular damage in transplanted hepatitis C virus-reinfected liver. Liver Transpl 2002; 8: 10-20 [PMID: 11799480 DOI: 10.1053/jlts.2002.30141]
9. Gane EJ, Naoumov NV, Qian KP, Mondelli MU, Maertens G, Portmann BC, Lau JY, Williams R. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology 1996; 110: 167-177 [PMID: 8536853 DOI: 10.1053/gast.1996.v110.pm8536853]
10. Gane EJ. The natural history of recurrent hepatitis C and what influences this. Liver Transpl 2008; 14 Suppl 2: S36-S44 [PMID: 18825724 DOI: 10.1002/lt.21646]
11. Sánchez-Fueyo A, Restrepo JC, Quintó L, Bruguera M, Grande L, Sánchez-Tapias JM, Rodés J, Rimola A. Impact of the recurrence of hepatitis C virus infection after liver transplantation on the long-term viability of the graft. Transplantation 2002; 73: 56-63 [PMID: 11792978 DOI: 10.1097/0000789 0-200201150-00010]
12. Berenguer M, Prieto M, Rayón JM, Mora J, Pastor M, Ortiz V, Carrasco D, San Juan F, Burgueño MD, Mir J, Berenguer J. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000; 32: 852-858 [PMID: 11003634 DOI: 10.1053/ jhep.2000.17924]
13. Charlton M. Natural history of hepatitis C and outcomes following liver transplantation. Clin Liver Dis 2003; 7: 585-602 [PMID: 14509528 DOI: 10.1016/S1089-3261(03)00046-1]
14. Terrault NA, Berenguer M. Treating hepatitis C infection in liver transplant recipients. Liver Transpl 2006; 12: 1192-1204 [PMID: 16868944 DOI: 10.1002/lt.20865]
15. Charlton M, Seaberg E, Wiesner R, Everhart J, Zetterman R, Lake J, Detre K, Hoofnagle J. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998; 28: 823-830 [PMID: 9731579 DOI: 10.1002/ hep.510280333]
16. Wiesner RH, Sorrell M, Villamil F. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003; 9: S1-S9 [PMID: 14586888 DOI: 10.1053/ jlts.2003.50268]
17. Roche B, Samuel D. Antiviral therapy in HCV-infected cirrhotics awaiting liver transplantation: A costly strategy for mixed virological results. J Hepatol 2009; 50: 652-654 [PMID: 19231019 DOI: 10.1016/j.jhep.2009.01.008]
18. Heathcote EJ, Shiffman ML, Cooksley WG, Dusheiko GM, Lee SS, Balart L, Reindollar R, Reddy RK, Wright TL, Lin A, Hoffman J, De Pamphilis J. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343: 1673-1680 [PMID: 11106716 DOI: 10.1056/ NEJM200012073432302]
19. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965 [PMID: 11583749 DOI: 10.1016/S0140-6736(01)06102-5]
20. Wright TL. Treatment of patients with hepatitis C and cirrhosis. Hepatology 2002; 36: S185-S194 [PMID: 12407593 DOI: 10.1053/jhep.2002.36812]
21. Abergel A, Hezode C, Leroy V, Barange K, Bronowicki JP, Tran A, Alric L, Castera L, Bernard PH, Henquell C, Lafeuille H, Ughetto S, Darcha C, Chevallier M, Martineau N, Dubost S, Randl K, Dhumeaux D, Bommelaer G, Bonny C. Peginterferon alpha-2b plus ribavirin for treatment of chronic hepatitis C with severe fibrosis: a multicentre randomized controlled trial comparing two doses of peginterferon alpha- 2b. J Viral Hepat 2006; 13: 811-820 [PMID: 17109680 DOI: 10.1111/j.1365-2893.2006.00768.x]
22. Forns X, García-Retortillo M, Serrano T, Feliu A, Suarez F, de la Mata M, García-Valdecasas JC, Navasa M, Rimola A, Rodés J. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 2003; 39: 389-396 [PMID: 12927925 DOI: 10.1016/S0168-8278(03)00310-6]
23. Everson GT, Trotter J, Forman L, Kugelmas M, Halprin A, Fey B, Ray C. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005; 42: 255-262 [PMID: 16025497 DOI: 10.1002/hep.20793]
24. Iacobellis A, Siciliano M, Perri F, Annicchiarico BE, Leandro G, Caruso N, Accadia L, Bombardieri G, Andriulli A. Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study. J Hepatol 2007; 46: 206-212 [PMID: 17125876 DOI: 10.1016/ j.jhep.2006.08.020]
25. Di Marco V, Almasio PL, Ferraro D, Calvaruso V, Alaimo G, Peralta S, Di Stefano R, Craxì A. Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial. J Hepatol 2007; 47: 484-491 [PMID: 17692985 DOI: 10.1016/j.jhep.2007.04.020]
26. Carrión JA, Martínez-Bauer E, Crespo G, Ramírez S, Pérezdel- Pulgar S, García-Valdecasas JC, Navasa M, Forns X. Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: A retrospective study. J Hepatol 2009; 50: 719-728 [PMID: 19217183 DOI: 10.1016/j.jhep.2008.11.015]
27. Thomas RM, Brems JJ, Guzman-Hartman G, Yong S, Cavaliere P, Van Thiel DH. Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation. Liver Transpl 2003; 9: 905-915 [PMID: 12942451 DOI: 10.1053/jlts.2003.50166]
28. Massoumi H, Elsiesy H, Khaitova V, Peterson B, Norkus E, Grewal P, Liu L, Chang C, Bach N, Schiano TD. An escalating dose regimen of pegylated interferon and ribavirin in HCV cirrhotic patients referred for liver transplant. Transplantation 2009; 88: 729-735 [PMID: 19741473 DOI: 10.1097/ TP.0b013e3181b2e0d1]
29. Helbling B, Jochum W, Stamenic I, Knöpfli M, Cerny A, Borovicka J, Gonvers JJ, Wilhelmi M, Dinges S, Müllhaupt B, Esteban A, Meyer-Wyss B, Renner EL. HCVrelated advanced fibrosis/cirrhosis: randomized controlled trial of pegylated interferon alpha-2a and ribavirin. J Viral Hepat 2006; 13: 762-769 [PMID: 17052276 DOI: 10.1111/ j.1365-2893.2006.00753.x]
30. Crippin JS, McCashland T, Terrault N, Sheiner P, Charlton MR. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 2002; 8: 350-355 [PMID: 11965579 DOI: 10.1053/jlts.2002.31748]
31. Tekin F, Gunsar F, Karasu Z, Akarca U, Ersoz G. Safety, tolerability, and efficacy of pegylated-interferon alfa-2a plus ribavirin in HCV-related decompensated cirrhotics. Aliment Pharmacol Ther 2008; 27: 1081-1085 [PMID: 18346186 DOI: 10.1111/j.1365-2036.2008.03680.x]
32. Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-355 [PMID: 14996676]
33. Féray C, Caccamo L, Alexander GJ, Ducot B, Gugenheim J, Casanovas T, Loinaz C, Gigou M, Burra P, Barkholt L, Esteban R, Bizollon T, Lerut J, Minello-Franza A, Bernard PH, Nachbaur K, Botta-Fridlund D, Bismuth H, Schalm SW, Samuel D. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group. Gastroenterology 1999; 117: 619-625 [PMID: 10464137 DOI: 10.1016/S0016-5085(99)70454-3]
34. Terrault NA. Hepatitis C therapy before and after liver transplantation. Liver Transpl 2008; 14 Suppl 2: S58-S66 [PMID: 18825697 DOI: 10.1002/lt.21624]
35. Gogu SR, Beckman BS, Wilson RB, Agrawal KC. Inhibitory effects of zidovudine in erythroid progenitor cells. Reversal with a combination of erythropoietin and interleukin-3. Biochem Pharmacol 1995; 50: 413-419 [PMID: 7646543 DOI: 10.1016/0006-2952(95)00134-L]
36. Russmann S, Grattagliano I, Portincasa P, Palmieri VO, Palasciano G. Ribavirin-induced anemia: mechanisms, risk factors and related targets for future research. Curr Med Chem 2006; 13: 3351-3357 [PMID: 17168855 DOI: 10.2174/092 986706778773059]
37. Afdhal NH, Dieterich DT, Pockros PJ, Schiff ER, Shiffman ML, Sulkowski MS, Wright T, Younossi Z, Goon BL, Tang KL, Bowers PJ. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology 2004; 126: 1302-1311 [PMID: 15131791 DOI: 10.1053/j.gastro.2004.01.027]
38. Del Rio RA, Post AB, Singer ME. Cost-effectiveness of hematologic growth factors for anemia occurring during hepatitis C combination therapy. Hepatology 2006; 44: 1598-1606 [PMID: 17133490 DOI: 10.1002/hep.21409]
39. Soza A, Everhart JE, Ghany MG, Doo E, Heller T, Promrat K, Park Y, Liang TJ, Hoofnagle JH. Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology 2002; 36: 1273-1279 [PMID: 12395340 DOI: 10.1053/jhep.2002.36502]
40. Berenguer M, Prieto M, San Juan F, Rayón JM, Martinez F, Carrasco D, Moya A, Orbis F, Mir J, Berenguer J. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002; 36: 202-210 [PMID: 12085366 DOI: 10.1053/ jhep.2002.33993]
41. Machicao VI, Bonatti H, Krishna M, Aqel BA, Lukens FJ, Nguyen JH, Rosser BG, Satyanarayana R, Grewal HP, Hewitt WR, Harnois DM, Crook JE, Steers JL, Dickson RC. Donor age affects fibrosis progression and graft survival after liver transplantation for hepatitis C. Transplantation 2004; 77: 84-92 [PMID: 14724440 DOI: 10.1097/01.TP.0000095896.07048.BB]
42. Wali M, Harrison RF, Gow PJ, Mutimer D. Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. Gut 2002; 51: 248-252 [PMID: 12117889 DOI: 10.1136/gut.51.2.248]
43. Samonakis DN, Triantos CK, Thalheimer U, Quaglia A, Leandro G, Teixeira R, Papatheodoridis GV, Sabin CA, Rolando N, Davies S, Dhillon AP, Griffiths P, Emery V, Patch DW, Davidson BR, Rolles K, Burroughs AK. Immunosuppression and donor age with respect to severity of HCV recurrence after liver transplantation. Liver Transpl 2005; 11: 386-395 [PMID: 15776454 DOI: 10.1002/lt.20344]
44. Lake JR, Shorr JS, Steffen BJ, Chu AH, Gordon RD, Wiesner RH. Differential effects of donor age in liver transplant recipients infected with hepatitis B, hepatitis C and without viral hepatitis. Am J Transplant 2005; 5: 549-557 [PMID: 15707410 DOI: 10.1111/j.1600-6143.2005.00741.x]
45. Berenguer M, Aguilera V, Prieto M, Ortiz C, Rodríguez M, Gentili F, Risalde B, Rubin A, Cañada R, Palau A, Rayón JM. Worse recent efficacy of antiviral therapy in liver transplant recipients with recurrent hepatitis C: impact of donor age and baseline cirrhosis. Liver Transpl 2009; 15: 738-746 [PMID: 19562707 DOI: 10.1002/lt.21707]
46. Fishbein TM, Fiel MI, Emre S, Cubukcu O, Guy SR, Schwartz ME, Miller CM, Sheiner PA. Use of livers with microvesicular fat safely expands the donor pool. Transplantation 1997; 64: 248-251 [PMID: 9256182 DOI: 10.1097/000078 90-199707270-00012]
47. Cieslak B, Lewandowski Z, Urban M, Ziarkiewicz-Wróblewska B, Krawczyk M. Microvesicular liver graft steatosis as a risk factor of initial poor function in relation to suboptimal donor parameters. Transplant Proc 2009; 41: 2985-2988 [PMID: 19857657 DOI: 10.1016/j.transproceed.2009.08.019]
48. Verran D, Kusyk T, Painter D, Fisher J, Koorey D, Strasser S, Stewart G, McCaughan G. Clinical experience gained from the use of 120 steatotic donor livers for orthotopic liver transplantation. Liver Transpl 2003; 9: 500-505 [PMID: 12740794 DOI: 10.1053/jlts.2003.50099]
49. Briceño J, Padillo J, Rufián S, Solórzano G, Pera C. Assignment of steatotic livers by the Mayo model for end-stage liver disease. Transpl Int 2005; 18: 577-583 [PMID: 15819807 DOI: 10.1111/j.1432-2277.2005.00091.x]
50. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33: 1358-1364 [PMID: 11391523 DOI: 10.1053/ jhep.2001.24432]
51. Botha JF, Thompson E, Gilroy R, Grant WJ, Mukherjee S, Lyden ER, Fox IJ, Sudan DL, Shaw BW, Langnas AN. Mild donor liver steatosis has no impact on hepatitis C virus fibrosis progression following liver transplantation. Liver Int 2007; 27: 758-763 [PMID: 17617118 DOI: 10.1111/ j.1478-3231.2007.01490.x]
52. Burra P, Loreno M, Russo FP, Germani G, Galligioni A, Senzolo M, Cillo U, Zanus G, Fagiuoli S, Rugge M. Donor livers with steatosis are safe to use in hepatitis C virus-positive recipients. Liver Transpl 2009; 15: 619-628 [PMID: 19479805 DOI: 10.1002/lt.21761]
53. Briceño J, Ciria R, Pleguezuelo M, de la Mata M, Muntané J, Naranjo A, Sánchez-Hidalgo J, Marchal T, Rufián S, López- Cillero P. Impact of donor graft steatosis on overall outcome and viral recurrence after liver transplantation for hepatitis C virus cirrhosis. Liver Transpl 2009; 15: 37-48 [PMID: 19109846 DOI: 10.1002/lt.21566]
54. Yilmaz N, Shiffman ML. Impact of the donor liver with steatosis in patients with hepatitis C virus: not so FAst. Liver Transpl 2009; 15: 4-6 [PMID: 19109836 DOI: 10.1002/lt.21661]
55. Baiocchi L, Tisone G, Palmieri G, Rapicetta M, Pisani F, Orlando G, Casciani CU, Angelico M. Hepatic steatosis: a specific sign of hepatitis C reinfection after liver transplantation. Liver Transpl Surg 1998; 4: 441-447 [PMID: 9791153 DOI: 10.1002/lt.500040613]
56. Machicao VI, Krishna M, Bonatti H, Aqel BA, Nguyen JH, Weigand SD, Rosser BG, Hughes C, Dickson RC. Hepatitis C recurrence is not associated with allograft steatosis within the first year after liver transplantation. Liver Transpl 2004; 10: 599-606 [PMID: 15108251 DOI: 10.1002/lt.20107]
57. Garcia-Retortillo M, Forns X, Llovet JM, Navasa M, Feliu A, Massaguer A, Bruguera M, Fuster J, Garcia-Valdecasas JC, Rimola A. Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation. Hepatology 2004; 40: 699-707 [PMID: 15349910 DOI: 10.1002/ hep.20357]
58. Shiffman ML, Stravitz RT, Contos MJ, Mills AS, Sterling RK, Luketic VA, Sanyal AJ, Cotterell A, Maluf D, Posner MP, Fisher RA. Histologic recurrence of chronic hepatitis C virus in patients after living donor and deceased donor liver transplantation. Liver Transpl 2004; 10: 1248-1255 [PMID: 15376308 DOI: 10.1002/lt.20232]
59. Guo L, Orrego M, Rodriguez-Luna H, Balan V, Byrne T, Chopra K, Douglas DD, Harrison E, Moss A, Reddy KS, Williams JW, Rakela J, Mulligan D, Vargas HE. Living donor liver transplantation for hepatitis C-related cirrhosis: no difference in histological recurrence when compared to deceased donor liver transplantation recipients. Liver Transpl 2006; 12: 560-565 [PMID: 16555313 DOI: 10.1002/lt.20660]
60. Schmeding M, Neumann UP, Puhl G, Bahra M, Neuhaus R, Neuhaus P. Hepatitis C recurrence and fibrosis progression are not increased after living donor liver transplantation: a single-center study of 289 patients. Liver Transpl 2007; 13: 687-692 [PMID: 17457911 DOI: 10.1002/lt.21138]
61. Humar A, Horn K, Kalis A, Glessing B, Payne WD, Lake J. Living donor and split-liver transplants in hepatitis C recipients: does liver regeneration increase the risk for recurrence? Am J Transplant 2005; 5: 399-405 [PMID: 15644001 DOI: 10.1111/j.1600-6143.2004.00704.x]
62. Lawal A, Ghobrial R, Te H, Artinian L, Eastwood D, Schiano TD. Comparison of hepatitis C histological recurrence rates and patient survival between split and deceased donor liver transplantation. Transplant Proc 2007; 39: 3261-3265 [PMID: 18089367 DOI: 10.1016/j.transproceed.2007.08.106]
63. Selzner N, Girgrah N, Lilly L, Guindi M, Selzner M, Therapondos G, Adeyi O, McGilvray I, Cattral M, Greig PD, Grant D, Levy G, Renner EL. The difference in the fibrosis progression of recurrent hepatitis C after live donor liver transplantation versus deceased donor liver transplantation is attributable to the difference in donor age. Liver Transpl 2008; 14: 1778-1786 [PMID: 19025914 DOI: 10.1002/lt.21598]
64. Marroquin CE, Marino G, Kuo PC, Plotkin JS, Rustgi VK, Lu AD, Edwards E, Taranto S, Johnson LB. Transplantation of hepatitis C-positive livers in hepatitis C-positive patients is equivalent to transplanting hepatitis C-negative livers. Liver Transpl 2001; 7: 762-768 [PMID: 11552208 DOI: 10.1053/ jlts.2001.27088]
65. Khapra AP, Agarwal K, Fiel MI, Kontorinis N, Hossain S, Emre S, Schiano TD. Impact of donor age on survival and fibrosis progression in patients with hepatitis C undergoing liver transplantation using HCV+ allografts. Liver Transpl 2006; 12: 1496-1503 [PMID: 16964597 DOI: 10.1002/lt.20849]
66. Humar A, Kumar D, Raboud J, Caliendo AM, Moussa G, Levy G, Mazzulli T. Interactions between cytomegalovirus, human herpesvirus-6, and the recurrence of hepatitis C after liver transplantation. Am J Transplant 2002; 2: 461-466 [PMID: 12123213 DOI: 10.1034/j.1600-6143.2002.20511.x]
67. Burak KW, Kremers WK, Batts KP, Wiesner RH, Rosen CB, Razonable RR, Paya CV, Charlton MR. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transpl 2002; 8: 362-369 [PMID: 11965581 DOI: 10.1053/ jlts.2002.32282]
68. Duclos-Vallée JC, Féray C, Sebagh M, Teicher E, Roque- Afonso AM, Roche B, Azoulay D, Adam R, Bismuth H, Castaing D, Vittecoq D, Samuel D. Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2008; 47: 407-417 [PMID: 18098295 DOI: 10.1002/hep.21990]
69. Norris S, Taylor C, Muiesan P, Portmann BC, Knisely AS, Bowles M, Rela M, Heaton N, O'Grady JG. Outcomes of liver transplantation in HIV-infected individuals: the impact of HCV and HBV infection. Liver Transpl 2004; 10: 1271-1278 [PMID: 15376307 DOI: 10.1002/lt.20233]
70. Watt KD, Lyden ER, Gulizia JM, McCashland TM. Recurrent hepatitis C posttransplant: early preservation injury may predict poor outcome. Liver Transpl 2006; 12: 134-139 [PMID: 16382465 DOI: 10.1002/lt.20583]
71. Killackey MT, Gondolesi GE, Liu LU, Paramesh AS, Thung SN, Suriawinata A, Nguyen E, Roayaie S, Schwartz ME, Emre S, Schiano TD. Effect of ischemia-reperfusion on the incidence of acute cellular rejection and timing of histologic hepatitis C virus recurrence after liver transplantation. Transplant Proc 2008; 40: 1504-1510 [PMID: 18589139 DOI: 10.1016/j.transproceed.2008.03.101]
72. Briceño J, Ciria R, Pleguezuelo M, Naranjo A, Sánchez- Hidalgo J, Ruiz-Rabelo J, López-Cillero P, Luque A, de la Mata M, Rufián S. Contribution of marginal donors to liver transplantation for hepatitis C virus infection. Transplant Proc 2007; 39: 2297-2299 [PMID: 17889169 DOI: 10.1016/j.tra nsproceed.2007.07.069]
73. Lan X, Zhang MM, Pu CL, Guo CB, Kang Q, Li YC, Dai XK, Deng YH, Xiong Q, Ren ZM. Impact of human leukocyte antigen mismatching on outcomes of liver transplantation: a meta-analysis. World J Gastroenterol 2010; 16: 3457-3464 [PMID: 20632452 DOI: 10.3748/wjg.v16.i27.3457]
74. Gallegos-Orozco JF, Yosephy A, Noble B, Aqel BA, Byrne TJ, Carey EJ, Douglas DD, Mulligan D, Moss A, de Petris G, Williams JW, Rakela J, Vargas HE. Natural history of postliver transplantation hepatitis C: A review of factors that may influence its course. Liver Transpl 2009; 15: 1872-1881 [PMID: 19938138 DOI: 10.1002/lt.21954]
75. Langrehr JM, Puhl G, Bahra M, Schmeding M, Spinelli A, Berg T, Schönemann C, Krenn V, Neuhaus P, Neumann UP. Influence of donor/recipient HLA-matching on outcome and recurrence of hepatitis C after liver transplantation. Liver Transpl 2006; 12: 644-651 [PMID: 16555324 DOI: 10.1002/ lt.20648]
76. Belli LS, Burra P, Poli F, Battista Alberti A, Silini E, Zavaglia C, Fagiuoli S, Prando D, Espadas de Arias A, Boninsegna S, Tinelli C, Scalamogna M, de Carlis L, Pinzello G. HLA-DRB1 donor-recipient mismatch affects the outcome of hepatitis C disease recurrence after liver transplantation. Gastroenterology 2006; 130: 695-702 [PMID: 16530511 DOI: 10.1053/ j.gastro.2005.11.013]
77. Balan V, Ruppert K, Demetris AJ, Ledneva T, Duquesnoy RJ, Detre KM, Wei YL, Rakela J, Schafer DF, Roberts JP, Everhart JE, Wiesner RH. Long-term outcome of human leukocyte antigen mismatching in liver transplantation: results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Hepatology 2008; 48: 878-888 [PMID: 18752327 DOI: 10.1002/hep.22435]
78. Yoshizawa A, Takada Y, Fujimoto Y, Koshiba T, Haga H, Nabeshima S, Uemoto S. Liver transplantation from an identical twin without immunosuppression, with early recurrence of hepatitis C. Am J Transplant 2006; 6: 2812-2816 [PMID: 16939511 DOI: 10.1111/j.1600-6143.2006.01531.x]
79. Kimball P, Baker M, Fisher RA. Allograft TNFbeta and IL16 polymorphisms influence HCV recurrence and severity after liver transplantation. Liver Transpl 2006; 12: 247-252 [PMID: 16447204 DOI: 10.1002/lt.20611]
80. Tambur AR, Ortegel JW, Ben-Ari Z, Shabtai E, Klein T, Michowiz R, Tur-Kaspa R, Mor E. Role of cytokine gene polymorphism in hepatitis C recurrence and allograft rejection among liver transplant recipients. Transplantation 2001; 71: 1475-1480 [PMID: 11391238 DOI: 10.1097/00007890-20010527 0-00020]
81. Rosen HR, Doherty DG, Madrigal-Estebas L, O'Farrelly C, Golden-Mason L. Pretransplantation CD56(+) innate lymphocyte populations associated with severity of hepatitis C virus recurrence. Liver Transpl 2008; 14: 31-40 [PMID: 18161829 DOI: 10.1002/lt.21265]
82. Golden-Mason L. Natural killer cells play divergent roles in shaping the outcome of hepatitis C virus recurrence following liver transplantation. Liver Transpl 2009; 15: 357-359 [PMID: 19326413 DOI: 10.1002/lt.21701]
83. de Arias AE, Haworth SE, Defeo TM, Poli F. Natural killer cells in hepatitis C virus recurrence following liver transplantation: what role do they play? Expert Rev Gastroenterol Hepatol 2009; 3: 329-332 [PMID: 19673619 DOI: 10.1586/ egh.09.29]
84. Pearlman BL. The IL-28 genotype: how it will affect the care of patients with hepatitis C virus infection. Curr Gastroenterol Rep 2011; 13: 78-86 [PMID: 21080244 DOI: 10.1007/ s11894-010-0161-9]
85. Aparicio E, Parera M, Franco S, Pérez-Alvarez N, Tural C, Clotet B, Martínez MA. IL28B SNP rs8099917 is strongly associated with pegylated interferon-a and ribavirin therapy treatment failure in HCV/HIV-1 coinfected patients. PLoS One 2010; 5: e13771 [PMID: 21048934 DOI: 10.1371/journal. pone.0013771]
86. Knobler H, Schihmanter R, Zifroni A, Fenakel G, Schattner A. Increased risk of type 2 diabetes in noncirrhotic patients with chronic hepatitis C virus infection. Mayo Clin Proc 2000; 75: 355-359 [PMID: 10761489 DOI: 10.4065/75.4.355]
87. Svegliati-Baroni G, Ridolfi F, Di Sario A, Casini A, Marucci L, Gaggiotti G, Orlandoni P, Macarri G, Perego L, Benedetti A, Folli F. Insulin and insulin-like growth factor-1 stimulate proliferation and type I collagen accumulation by human hepatic stellate cells: differential effects on signal transduction pathways. Hepatology 1999; 29: 1743-1751 [PMID: 10347117 DOI: 10.1002/hep.510290632]
88. Foxton MR, Quaglia A, Muiesan P, Heneghan MA, Portmann B, Norris S, Heaton ND, O'Grady JG. The impact of diabetes mellitus on fibrosis progression in patients transplanted for hepatitis C. Am J Transplant 2006; 6: 1922-1929 [PMID: 16780550 DOI: 10.1111/j.1600-6143.2006.01408.x]
89. Hanouneh IA, Feldstein AE, McCullough AJ, Miller C, Aucejo F, Yerian L, Lopez R, Zein NN. The significance of metabolic syndrome in the setting of recurrent hepatitis C after liver transplantation. Liver Transpl 2008; 14: 1287-1293 [PMID: 18756451 DOI: 10.1002/lt.21524]
90. Veldt BJ, Poterucha JJ, Watt KD, Wiesner RH, Hay JE, Rosen CB, Heimbach JK, Janssen HL, Charlton MR. Insulin resistance, serum adipokines and risk of fibrosis progression in patients transplanted for hepatitis C. Am J Transplant 2009; 9: 1406-1413 [PMID: 19459812 DOI: 10.1111/ j.1600-6143.2009.02642.x]
91. Sánchez-Pérez B, Aranda Narváez JM, Santoyo Santoyo J, Fernández-Aguilar JL, Suárez Muñoz MA, González- Sánchez AJ, Pérez Daga JA, Ramírez Plaza CP, Carrasco Campos J, Jiménez Mazure C, Becerra Ortíz R. Influence of immunosuppression and effect of hepatitis C virus on new onset of diabetes mellitus in liver transplant recipients. Transplant Proc 2008; 40: 2994-2996 [PMID: 19010171 DOI: 10.1016/j.transproceed.2008.08.116]
92. McCaughan GW, Zekry A. Impact of immunosuppression on immunopathogenesis of liver damage in hepatitis C virus-infected recipients following liver transplantation. Liver Transpl 2003; 9: S21-S27 [PMID: 14586891 DOI: 10.1053/ jlts.2003.50269]
93. De Ruvo N, Cucchetti A, Lauro A, Masetti M, Cautero N, Di Benedetto F, Dazzi A, Del Gaudio M, Ravaioli M, Di Francesco F, Molteni G, Ramacciato G, Risaliti A, Pinna AD. Preliminary results of a "prope" tolerogenic regimen with thymoglobulin pretreatment and hepatitis C virus recurrence in liver transplantation. Transplantation 2005; 80: 8-12 [PMID: 16003226 DOI: 10.1097/01.TP.0000164349.54297.95]
94. Ohira M, Ishiyama K, Tanaka Y, Doskali M, Igarashi Y, Tashiro H, Hiraga N, Imamura M, Sakamoto N, Asahara T, Chayama K, Ohdan H. Adoptive immunotherapy with liver allograft-derived lymphocytes induces anti-HCV activity after liver transplantation in humans and humanized mice. J Clin Invest 2009; 119: 3226-3235 [PMID: 19805910 DOI: 10.1172/JCI38374]
95. Pawlotsky JM, Chevaliez S. Preventing hepatitis C virus recurrence in liver transplant recipients: a role for adoptive immunotherapy? Hepatology 2010; 51: 1072-1076 [PMID: 20198701 DOI: 10.1002/hep.23579]
96. Gedaly R, Clifford TM, McHugh PP, Jeon H, Johnston TD, Ranjan D. Prevalent immunosuppressive strategies in liver transplantation for hepatitis C: results of a multi-center international survey. Transpl Int 2008; 21: 867-872 [PMID: 18498313 DOI: 10.1111/j.1432-2277.2008.00699.x]
97. Sheiner PA, Schwartz ME, Mor E, Schluger LK, Theise N, Kishikawa K, Kolesnikov V, Bodenheimer H, Emre S, Miller CM. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995; 21: 30-34 [PMID: 7806166 DOI: 10.1002/hep.1840210107]
98. Berenguer M, Aguilera V, Prieto M, San Juan F, Rayón JM, Benlloch S, Berenguer J. Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression. J Hepatol 2006; 44: 717-722 [PMID: 16487616 DOI: 10.1016/j.jhep.2006.01.005]
99. Vivarelli M, Burra P, La Barba G, Canova D, Senzolo M, Cucchetti A, D'Errico A, Guido M, Merenda R, Neri D, Zanello M, Giannini FM, Grazi GL, Cillo U, Pinna AD. Influence of steroids on HCV recurrence after liver transplantation: A prospective study. J Hepatol 2007; 47: 793-798 [PMID: 17928091 DOI: 10.1016/j.jhep.2007.07.023]
100. Segev DL, Sozio SM, Shin EJ, Nazarian SM, Nathan H, Thuluvath PJ, Montgomery RA, Cameron AM, Maley WR. Steroid avoidance in liver transplantation: meta-analysis and meta-regression of randomized trials. Liver Transpl 2008; 14: 512-525 [PMID: 18383081 DOI: 10.1002/lt.21396]
101. Nakagawa M, Sakamoto N, Enomoto N, Tanabe Y, Kanazawa N, Koyama T, Kurosaki M, Maekawa S, Yamashiro T, Chen CH, Itsui Y, Kakinuma S, Watanabe M. Specific inhibition of hepatitis C virus replication by cyclosporin A. Biochem Biophys Res Commun 2004; 313: 42-47 [PMID: 14672695 DOI: 10.1016/j.bbrc.2003.11.080]
102. Berenguer M, Royuela A, Zamora J. Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a metaanalysis. Liver Transpl 2007; 13: 21-29 [PMID: 17192906 DOI: 10.1002/lt.21035]
103. Levy G, Villamil F, Samuel D, Sanjuan F, Grazi GL, Wu Y, Marotta P, Boillot O, Muehlbacher F, Klintmalm G. Results of lis2t, a multicenter, randomized study comparing cyclosporine microemulsion with C2 monitoring and tacrolimus with C0 monitoring in de novo liver transplantation. Transplantation 2004; 77: 1632-1638 [PMID: 15201658 DOI: 10.1097/01.TP.0000129095.51031.42]
104. Inoue K, Sekiyama K, Yamada M, Watanabe T, Yasuda H, Yoshiba M. Combined interferon alpha2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial. J Gastroenterol 2003; 38: 567-572 [PMID: 12825133]
105. Firpi RJ, Zhu H, Morelli G, Abdelmalek MF, Soldevila- Pico C, Machicao VI, Cabrera R, Reed AI, Liu C, Nelson DR. Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. Liver Transpl 2006; 12: 51-57 [PMID: 16382464 DOI: 10.1002/lt.20532]
106. Firpi RJ, Soldevila-Pico C, Morelli GG, Cabrera R, Levy C, Clark VC, Suman A, Michaels A, Chen C, Nelson DR. The use of cyclosporine for recurrent hepatitis C after liver transplant: a randomized pilot study. Dig Dis Sci 2010; 55: 196-203 [PMID: 19798576 DOI: 10.1007/s10620-009-0981-3]
107. Triyatni M, Vergalla J, Davis AR, Hadlock KG, Foung SK, Liang TJ. Structural features of envelope proteins on hepatitis C virus-like particles as determined by anti-envelope monoclonal antibodies and CD81 binding. Virology 2002; 298: 124-132 [PMID: 12093180 DOI: 10.1006/viro.2002.1463]
108. Tarr AW, Owsianka AM, Timms JM, McClure CP, Brown RJ, Hickling TP, Pietschmann T, Bartenschlager R, Patel AH, Ball JK. Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33. Hepatology 2006; 43: 592-601 [PMID: 16496330 DOI: 10.1002/hep.21088]
109. Bartosch B, Dubuisson J, Cosset FL. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med 2003; 197: 633-642 [PMID: 12615904 DOI: 10.1084/jem.20021756]
110. Willems B, Ede M, Marotta P, Wall W, Greig P, Lilly L, Kneteman N, Wong W, Roy A, Marleau D, Scudamore C, Yoshida E, Rinfret A. Anti-HCV human immunoglobulins for the prevention of graft infection in HCV-related liver transplantation, a pilot study. J Hepatol 2002; 36: S96A [DOI: 10.1016/S0168-8278(02)80095-2]
111. Schiano TD, Charlton M, Younossi Z, Galun E, Pruett T, Tur-Kaspa R, Eren R, Dagan S, Graham N, Williams PV, Andrews J. Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: results of a phase 2 randomized study. Liver Transpl 2006; 12: 1381-1389 [PMID: 16933235 DOI: 10.1002/lt.20876]
112. Davis GL, Nelson DR, Terrault N, Pruett TL, Schiano TD, Fletcher CV, Sapan CV, Riser LN, Li Y, Whitley RJ, Gnann JW. A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients. Liver Transpl 2005; 11: 941-949 [PMID: 16035063 DOI: 10.1002/lt.20405]
113. Gurusamy KS, Tsochatzis E, Davidson BR, Burroughs AK. Antiviral prophylactic intervention for chronic hepatitis C virus in patients undergoing liver transplantation. Cochrane Database Syst Rev 2010; (12): CD006573 [PMID: 21154370]
114. Peveling-Oberhag J, Zeuzem S, Hofmann WP. Antiviral therapy of chronic hepatitis C in patients with advanced liver disease and after liver transplantation. Med Microbiol Immunol 2010; 199: 1-10 [PMID: 19902246 DOI: 10.1007/ s00430-009-0131-8]
115. Gurusamy KS, Osmani B, Xirouchakis E, Burroughs AK, Davidson BR. Antiviral therapy for recurrent liver graft infection with hepatitis C virus. Cochrane Database Syst Rev 2009; (1): CD006803 [PMID: 19160303]
116. Carrión JA, Navasa M, García-Retortillo M, García-Pagan JC, Crespo G, Bruguera M, Bosch J, Forns X. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology 2007; 132: 1746-1756 [PMID: 17484872 DOI: 10.1053/ j.gastro.2007.03.041]
117. Saab S, Hunt DR, Stone MA, McClune A, Tong MJ. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model. Liver Transpl 2010; 16: 748-759 [PMID: 20517909]
118. Lange CM, Sarrazin C, Zeuzem S. Review article: specifically targeted anti-viral therapy for hepatitis C - a new era in therapy. Aliment Pharmacol Ther 2010; 32: 14-28 [PMID: 20374226 DOI: 10.1111/j.1365-2036.2010.04317.x]
119. McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, Heathcote EJ, Zeuzem S, Reesink HW, Garg J, Bsharat M, George S, Kauffman RS, Adda N, Di Bisceglie AM. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362: 1292-1303 [PMID: 20375406 DOI: 10.1056/NEJMoa0908014]
120. Kanda T, Imazeki F, Yokosuka O. New antiviral therapies for chronic hepatitis C. Hepatol Int 2010; 4: 548-561 [PMID: 21063477 DOI: 10.1007/s12072-010-9193-3]